Venetoclax After TKI to Target Persisting Stem Cells in CML
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms VARIANT
Most Recent Events
- 10 Mar 2025 Planned End Date changed from 1 Dec 2025 to 31 Jan 2026.
- 10 Mar 2025 Planned primary completion date changed from 1 Dec 2025 to 31 Jan 2026.
- 10 Mar 2025 Status changed from recruiting to active, no longer recruiting.